Elementis (LSE:ELM) continues to buy back shares as its portfolio simplification feeds through to higher margins, with investors watching whether the chemicals group can hold its full-year targets amid a volatile macro backdrop.

Elementis, the FTSE 250 specialty chemicals group behind additives used in coatings and personal care products, has kept up a steady pace of share repurchases into October. A disclosure covering the week of 5 to 9 October showed the company bought back 344,616 shares across several trading venues at prices between roughly 177p and 184p. After cancellation, the group had a little under 568 million shares in issue, with around 3 million held in treasury. The purchases are part of a programme of about £25m launched on 3 June, funded from the proceeds of the sale of its pharmaceutical manufacturing business.

Portfolio clean-up delivers margin progress

The buyback forms one strand of a broader transformation under chief executive Luc van Ravenstein, who has described simplifying the portfolio as his first priority. Over the past two years Elementis has sold its talc operations and, more recently, its pharmaceutical manufacturing unit to Associated British Foods for an enterprise value of €34.3m. The aim is to create a more focused specialty additives business with higher returns and less exposure to cyclical, lower-margin activities.

Half-year results published on 30 July suggested the strategy is gaining traction. Revenue for the six months to 30 June rose 9.4% to $318.2m, or 4.7% on an organic constant-currency basis. Adjusted operating profit increased 16.4% to $73.2m, lifting the adjusted operating margin to 23.0% from 21.6% a year earlier. Adjusted diluted earnings per share grew almost 29% to 8.5 cents, and the board raised the interim dividend by 15.4% to 1.5 cents, which was paid in sterling on 25 September. Van Ravenstein said he was excited to see real progress coming through in the financial results.

Balance sheet and outlook

The disposal proceeds and cash generation have also strengthened the balance sheet. Net debt fell to $163.8m at the end of June from $185.4m at the start of the year, equivalent to about 1.1 times EBITDA, giving the board room to return capital while continuing to invest in innovation and commercial capability. The interim figures also included a $1.2m refund of US tariffs following a February ruling by the US Supreme Court, which was treated as an adjusting item.

On outlook, Elementis said it expected full-year performance to be in line with market expectations, which at the time pointed to adjusted operating profit of around $132.5m for 2026. The company flagged that it was monitoring risks linked to the conflict in the Middle East, which has affected energy and raw material markets. Shares have traded in a fairly narrow range around 180p in recent weeks, reflecting a balance between the improving margin story and caution over demand in industrial and coatings end-markets.

What comes next

The chemicals sector has had a difficult period, with many European and UK producers reporting subdued volumes as customers remain cautious on restocking. Elementis (LSE:ELM) has sought to differentiate itself by concentrating on niche additives where pricing is supported by performance and technical service rather than commodity dynamics. Its exposure to personal care, where it supplies ingredients for cosmetics and antiperspirants, has provided a degree of resilience alongside the more cyclical coatings business.

Investors will look to the group's next trading update for confirmation that organic growth and margin expansion are holding up in the second half, and for further detail on how management intends to deploy capital once the current buyback is complete. Progress towards the medium-term margin ambitions set out by management will also be closely tracked.